A potential new antidepressant and antianxiety treatment with a unique mechanism of action has been developed by scientists at the University of Bath.
The compound has shown significant potential after studies in mice. The research is published in the British Journal of Pharmacology.
Around one in six adults will experience depression in their lifetimes. New drugs to treat depression in particular are needed because many existing antidepressants don’t work in up to 50% of patients. This new University of Bath compound, known as BU10119, works in a different way to the most common antidepressant drugs; selective serotonin reuptake inhibitors (SSRIs), and may therefore offer a new potential treatment for those in whom SSRIs don’t work.
Unlike SSRIs which target the serotonin system in the brain, BU10119 works by blocking receptors called kappa opioid receptors. Blocking these receptors has been shown to have anti-depressant like effects in mice.
In a series of laboratory trials, mice given BU10119 demonstrated behaviours consistent with providing antidepressant–like effects.
Dr Sarah Bailey, Senior Lecturer in the Department of Pharmacy & Pharmacology at the University of Bath, said: “I’m really quite excited by the potential of this compound. Developing new medicines is why I got into pharmacology and, in 20 years of research, this is the closest I have come to a new compound that might translate towards the clinic. It’s promising, but that said, we are still at an early stage, these experiments are in mice and further research is still required for example to establish safety.
“SSRIs can work very well for some patients, but we know they don’t work for everyone which is one reason why developing new antidepressant and antianxiety drugs could be really beneficial.”
The researchers were inspired to develop the compound after previous University of Bath research showed that a combination of two existing drugs, buprenorphine and naltrexone, had potential as an antidepressant. BU10119 combines the effects of this combination in one drug.
Professor Stephen Husbands, Head of Medicinal Chemistry at the University of Bath added: “This research builds on our previous work which showed that combining buprenorphine and naltrexone can give antidepressant effects in mice. By combining the effects of both drugs in one molecule we hope that a safe and effective drug will eventually be the outcome. BU10119 is part of a series of compounds now licensed to, and under development with, Orexigen Therapeutics.”
The study was funded a by a National Institute on Drug Abuse grant and a PhD scholarship from the Government of Saudi Arabia.
The University of Bath has signed the Concordat on Openness on Animal Research. The University is committed to enhancing our communications with the media and public about our research using animals. Find out more: http://www.bath.ac.uk/collections/animal-research/
Learn more: New drug shows potential as a different kind of antidepressant in mouse trials
The Latest on: Depression and anxiety
[google_news title=”” keyword=”depression and anxiety” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]- Prospect League aligns with Athletes Against Anxiety and Depressionon May 7, 2024 at 12:00 pm
The Prospect League is partnering with Athletes Against Anxiety and Depression (AAAD) beginning with the 2024 season and becoming the first and only summer collegiate baseball league to make mental ...
- Using AI and social media to track depression in communities could offer more reliable assessments than surveyson May 7, 2024 at 10:12 am
A study that used artificial intelligence (AI) and social media posts to assess the rates of depression and anxiety in nearly half of American counties found that the AI-generated measurements ...
- AA Unlikely to Cause Anxiety, Depression but May Be Affected by Mental Illnesson May 7, 2024 at 8:47 am
A Mendelian randomization study using genetic analysis found that alopecia areata (AA) increases the risk of anxiety and depression, but not the other way around, providing unique evidence for a ...
- Thrive Postpartum introduces innovative platform and podcast to support mothers with postpartum depression and anxietyon May 7, 2024 at 5:35 am
Listen to this article Thrive Postpartum™ proudly announces the launch of its online platform and the premiere of its new podcast, “Let’s Thrive Postpartum,” designed specifically to support mothers ...
- There’s hope in the darkness of depression and anxietyon May 7, 2024 at 3:48 am
For many Christians, the pressure to always appear joyful and steadfast in their faith can exacerbate feelings of anxiety and depression. The expectation of being strong in their beliefs while ...
- Depression Newson May 4, 2024 at 5:00 pm
Brain Stimulation Treatment May Improve Depression, Anxiety in Older Adults Apr. 10, 2024 — A noninvasive brain stimulation treatment improved depression and anxiety symptoms among older adults ...
- Treating anxiety, depression significantly impacts heart disease outcomeson May 2, 2024 at 8:55 am
Treating anxiety and depression significantly reduced emergency room visits and rehospitalizations among people with heart disease, according to a study by researchers at The Ohio State University ...
- Virtual reality could revolutionize mental-health treatments, including ketamine therapy, for conditions like depression and anxietyon May 2, 2024 at 7:25 am
Here's how virtual reality is transforming mental-health treatments such as ketamine therapy for conditions like depression, PTSD, and body dysmorphia.
- The signs to look out for when it comes to birth-related depression and anxietyon May 1, 2024 at 11:46 pm
Birth-related depression and anxiety. It's more than just the "baby blues." Birth mothers have a 1-in-5 chance of experiencing depression and anxiety during pregnancy and the year after birth.
- People with depression and anxiety set to lose sickness benefitson April 29, 2024 at 5:00 pm
People with depression or anxiety could lose access to benefits as part of the Government’s major welfare reforms. Mel Stride is set to announce plans to overhaul the way disability benefits ...
via Google News and Bing News